SCHEMBL2447775

SCHEMBL2447775

CCOC(=O)c1cnc(Cl)cc1NCc1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 4/20 0.47
KDM4E B2RXH2 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALOX15 P16050 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HPGD P15428 1/20 0.45
GAA P10253 2/20 0.44
LMNA P02545 1/20 0.44
VNN1 O95497 1/20 0.43
PDE5A O76074 2/20 0.43
ADRA1D P25100 1/20 0.43
ADRA1A P35348 1/20 0.43
ADRA1B P35368 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30065035 0.85 NPSR1 (0.62) RAB9AALDH1A1MAPTKDM4EALOX15
SCHEMBL22208165 0.85 NPSR1 (0.62) RAB9AALDH1A1MAPTKDM4EALOX15
SCHEMBL12279848 0.83 AURKA (0.50) RAB9AALDH1A1MAPTKDM4ECYP1A2
SCHEMBL27622822 0.82 ADRA1D (0.60) RAB9AALDH1A1MAPTKDM4ECYP1A2
SCHEMBL4277553 0.81 ALDH1A1 (0.45) RAB9AALDH1A1MAPTKDM4EALOX15
SCHEMBL2693303 0.79 GAA (0.49) RAB9AALDH1A1MAPTSMN1; SMN2NPSR1
SCHEMBL15584189 0.78 KDM4E (0.44) RAB9AALDH1A1MAPTKDM4EALOX15
SCHEMBL16491990 0.78 KDM4E (0.50) RAB9AALDH1A1MAPTKDM4ECYP1A2
SCHEMBL502084 0.78 ATM (0.51) RAB9AALDH1A1MAPTKDM4ESMN1; SMN2
SCHEMBL31252847 0.78 GAA (0.56) RAB9AALDH1A1MAPTKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
US-8575153-B2 Pyridine-3-carboxyamide derivative KOWA COMPANY, LTD. (JP) 2013-11-05 US disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
EP-2380877-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE Kowa Company, Ltd. (JP) 2011-10-26 EP disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE KOWA COMPANY, LTD. (JP) 2011-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237590-A1 PYRIDINE-3-CARBOXYAMIDE DERIVATIVE JAK3, JAK1, UACA RAB9A 2317/4885ALDH1A1 2676/4885MAPT 1412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.